Alpha-Synuclein Aggregation Inhibitors

Alpha-Synuclein Aggregation Inhibitors

Introduction

Alpha Synuclein Aggregation Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">Alpha-Synuclein Aggregation Inhibitors</th></tr>
<tr><td><b>Category</b></td><td>Disease-Modifying Therapy</td></tr>
<tr><td><b>Target Diseases</b></td><td>Parkinson's Disease, Dementia with Lewy Bodies, Multiple System Atrophy, Pure Autonomic Failure</td></tr>
<tr><td><b>Mechanism</b></td><td>Inhibit α-synuclein nucleation, aggregation, and fibril formation</td></tr>
<tr><td><b>Development Stage</b></td><td>Clinical trials (Phase I-III)</td></tr>
</table>
</div>

Overview

Alpha-Synuclein Aggregation Inhibitors

Introduction

Alpha Synuclein Aggregation Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">Alpha-Synuclein Aggregation Inhibitors</th></tr>
<tr><td><b>Category</b></td><td>Disease-Modifying Therapy</td></tr>
<tr><td><b>Target Diseases</b></td><td>Parkinson's Disease, Dementia with Lewy Bodies, Multiple System Atrophy, Pure Autonomic Failure</td></tr>
<tr><td><b>Mechanism</b></td><td>Inhibit α-synuclein nucleation, aggregation, and fibril formation</td></tr>
<tr><td><b>Development Stage</b></td><td>Clinical trials (Phase I-III)</td></tr>
</table>
</div>

Overview

[Alpha-synuclein](/proteins/alpha-synuclein) (alpha-syn) aggregation inhibitors represent the most promising disease-modifying approach for synucleinopathies. These small molecules and biological agents target the pathological aggregation of alpha-syn from soluble monomers into toxic oligomers and fibrils that form Lewy bodies and glial cytoplasmic inclusions. By preventing or reversing aggregation, these therapies aim to slow or halt disease progression^[1].

Pathological Basis

α-Syn Aggregation Cascade

The aggregation of α-syn follows a nucleation-dependent polymerization pathway:

Strains and Propagation

Different α-syn strains (oligomorphs) may explain the clinical heterogeneity of synucleinopathies:

• PD/DLB strains: Less aggressive, more localized
• MSA strains: More aggressive, glia-dependent propagation^[2]

Therapeutic Approaches

Small Molecule Inhibitors

Epigallocatechin-3-Gallate (EGCG)

Green tea polyphenol that directly binds α-syn and prevents aggregation. Clinical trials in PD showed reduced α-syn oligomers but inconsistent clinical outcomes^[3].

Status: Phase II completed

Curcumin and Analogs

Natural anthrax that stabilizes native α-syn conformation and inhibits fibril formation. Poor blood-brain barrier (BBB) penetration limits efficacy^[4].

Status: Preclinical/Phase I

Nicotine and Nicotinic Agonists

Nicotine reduces α-syn aggregation through α7-nAChR activation. Observational studies suggest reduced PD risk in smokers, but clinical trials showed limited efficacy^[5].

Status: Phase II (repurposing)

Synuclein-Interacting Compounds

• Anle138b: Oligomer modulator, completed Phase I^[6]
• NPT200-1: Calcium/calmodulin-dependent protein kinase inhibitor, Phase I^[7]

Immunotherapy

Active Immunization

Affitope PD01A/PD03A (Affiris)

• Synthetic peptide vaccines mimicking α-syn epitopes
• Induces antibodies against pathological α-syn
• Phase I showed safety and antibody generation^[8]

• Liposome-based vaccine with phosphorylated Ser129 α-syn
• Strong antibody response against pathological α-syn
• Phase Ib completed^[9]

Passive Immunization

Prasinezumab (RO7046015/PRX002) (Roche)

• Humanized monoclonal antibody against α-syn C-terminus
• Phase II PASADENA trial: Slowed motor progression^[10]
• Phase IIb PADOVA trial ongoing in early PD

• Antibody targeting pathological α-syn aggregates
• Phase I completed^[11]

• Antibody against α-syn fibrils and oligomers
• Phase II SENSIP trial showed mixed results^[12]

Clinical Trial Landscape

| Drug | Company | Mechanism | Phase | Status |
|------|---------|-----------|-------|--------|
| Prasinezumab | Roche | Passive immunization | IIb | Ongoing |
| ABBV-0805 | AbbVie | Passive immunization | I | Completed |
| BIIB054 | Biogen | Passive immunization | II | Completed |
| Affitope PD01A | Affiris | Active immunization | II | Ongoing |
| ACI-35 | AC Immune | Active immunization | Ib | Completed |
| Anle138b | MODAG | Oligomer modulator | I/II | Completed |

Biomarkers for Clinical Trials

Target Engagement Markers

• α-Synuclein RT-QuIC: Seed amplification from CSF^[13]
• Serum [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Neurodegeneration marker
• DaTscan: Dopaminergic neuron integrity

Clinical Endpoints

• MDS-UPDRS: Motor and non-motor symptoms
• MoCA: Cognitive assessment
• DATATOP: Composite progression measures

Challenges and Future Directions

Key Challenges

Combination Approaches

• Immunotherapy + small molecules: Complementary mechanisms
• α-syn + [tau](/proteins/tau)/amyloid: Triple pathology approaches
• Symptomatic + disease-modifying: Integrated treatment strategies

Background

The study of Alpha Synuclein Aggregation Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

^[1] Bridi JC, Hirth F. Mechanisms of α-Synuclein induced synucleinopathy in Parkinson's disease. J Neurosci. 2018;38(33):7555-7570.

^[2] Peelaerts W, Bousset L, Van der Perren A, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522(7556):340-344.

^[3] de la Mata M, Cotán J, Oropesa-Ávila M, et al. Epigallocatechin-3-gallate as a potential therapeutic agent for neurodegenerative diseases. Adv Nutr. 2015;6(5):565-568.

^[4] Rajeswari A, Sabesan M. Inhibition of alpha synuclein aggregation by curcumin - a computational and experimental study. J Mol Neurosci. 2020;70(8):1264-1277.

^[5] Quik M, O'Neill M, Perez XA. Nicotine and neuroprotection in Parkinson's disease. Neurotoxicology. 2019;73:120-129.

^[6] Wagner J, Ryazanov S, Leonov A, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases. Acta Neuropathol. 2013;126(5):795-813.

^[7] Khannot AS, Sava A, Liu Y, et al. NPT200-1: a novel small molecule inhibitor of α-synuclein aggregation. Neurotherapeutics. 2021;18(2):1063-1077.

^[8] Schneeberger A, Mandler M, Mattner F, Schmidt W. Affinity of α-synuclein vaccines in Parkinson's disease. J Parkinsons Dis. 2012;2(4):275-282.

^[9] Bucchieri F, Farina C, Frossi B, et al. ACI-35 liposomal vaccine induces robust anti-α-syn antibodies in Parkinson's disease. NPJ Parkinsons Dis. 2020;6:25.

^[10] Pagano G, Taylor KI, Anzures-Cabrera J, et al. Prasinezumab for early-stage Parkinson's disease: a randomized, double-blind, Phase II trial. Nat Med. 2022;28(10):2106-2112.

<sup>[11]</sup] Weintraub D, Raza S, Siderowf AD, et al. ABBV-0805, a monoclonal antibody against α-synuclein, in healthy volunteers. Mov Disord. 2022;37(9):1889-1896.

^[12] Berg D, et al. BIIB054 (cinmeron) in Parkinson's disease: Phase II SENSIP trial. Lancet Neurol. 2021;20(12):938-950.

^[13] Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Neurol. 2016;80(5):730-740.

See Also

• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-pathology)
• [Treatments: Parkinson's Disease](/content/treatments)
• [Treatments: Dementia with Lewy Bodies](/content/treatments)
• [Biomarkers: Alpha-Synuclein](/content/biomarkers)

External Links

• [Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org/research/research-funding/alpha-synuclein)
• [Parkinson's Foundation - Disease-Modifying Therapies](https://www.parkinson.org/Living-with-Parkinsons/Treatment/Care-Options/Disease-Modifying-Therapies)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
• [Gut Barrier Permeability-α-Synuclein Axis Modulation](/hypothesis/h-6c83282d) — <span style="color:#ffd54f;font-weight:600">0.60</span> · Target: CLDN1, OCLN, ZO1, MLCK
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1

Related Analyses:

• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;